Cell Therapeutics, Inc. Pops On Old News

August 23, 2006 – Cell Therapeutics jumped 25% on news that the American Journal of Clinical Oncology published details of its Phase I trial of Xyotax. In combination with radiation, the drug produced a response in 91% of patients with esophageal or gastric cancer. The data comes from a small Phase I trial that was originally reported at the 2005 ASCO meeting. We look at the drug and its clinical status...